“Patients with cancer don’t have time to wait for new treatments, so there is a strong need to compress the drug discovery ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca shared the topline result ... developed by Array BioPharma before AZ licensed the drug in 2003. The MEK 1/2 ...

Compugen (CGEN) has released an update. Compugen reported strong third-quarter financial results for 2024, with a net profit of $1.3 million, a ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...